PD L1 News and Research

RSS
HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

New method uses extracellular vesicles to enhance immunotherapy responses in glioblastoma

New method uses extracellular vesicles to enhance immunotherapy responses in glioblastoma

Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics

Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics

Researchers discover a vulnerability in immunotherapy-resistant triple-negative breast cancer

Researchers discover a vulnerability in immunotherapy-resistant triple-negative breast cancer

Breakthrough study shows immunotherapy can help prevent bladder cancer recurrence

Breakthrough study shows immunotherapy can help prevent bladder cancer recurrence

Combination immunotherapy outperforms durvalumab monotherapy in neoadjuvant NSCLC

Combination immunotherapy outperforms durvalumab monotherapy in neoadjuvant NSCLC

New trial shows promise of combination neoadjuvant immunotherapy for lung cancer

New trial shows promise of combination neoadjuvant immunotherapy for lung cancer

CheckMate 227 trial: Nivolumab + ipilimumab shows remarkable six-year survival benefits in metastatic NSCLC

CheckMate 227 trial: Nivolumab + ipilimumab shows remarkable six-year survival benefits in metastatic NSCLC

Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C-positive NSCLC at FDA advisory committee meeting

Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C-positive NSCLC at FDA advisory committee meeting

Light-driven bacteria could be used to target and kill cancer cells

Light-driven bacteria could be used to target and kill cancer cells

New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

Regulation of cytotoxic T-cell differentiation and exhaustion by mTOR signaling

Regulation of cytotoxic T-cell differentiation and exhaustion by mTOR signaling

Immunotherapy combination extends progression-free survival in patients with melanoma

Immunotherapy combination extends progression-free survival in patients with melanoma

Molecular insights: Detecting gene fusions offers new avenues for advanced cancer management

Molecular insights: Detecting gene fusions offers new avenues for advanced cancer management

Multifunctional Ga-based nanoparticles combine cancer phototherapy with immunotherapy

Multifunctional Ga-based nanoparticles combine cancer phototherapy with immunotherapy

Nutrition meets cancer therapy: How gut microbiome and diet impact immunotherapy success

Nutrition meets cancer therapy: How gut microbiome and diet impact immunotherapy success

Immunodiagnosis: Unleashing the potential of personalized immunotherapy

Immunodiagnosis: Unleashing the potential of personalized immunotherapy

High tumor monocyte content linked to better outcomes for esophageal cancer patients

High tumor monocyte content linked to better outcomes for esophageal cancer patients

Immunotherapy significantly improves overall survival for advanced NSCLC patients

Immunotherapy significantly improves overall survival for advanced NSCLC patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.